Indaptus Therapeutics (NASDAQ:INDP) Raised to “Sell” at Wall Street Zen

Indaptus Therapeutics (NASDAQ:INDP) was upgraded by Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Indaptus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $140.00.

Indaptus Therapeutics Stock Up 2.3%

Shares of NASDAQ:INDP opened at $3.63 on Friday. The company has a market cap of $4.02 million, a price-to-earnings ratio of -0.10 and a beta of 1.13. The firm’s 50-day simple moving average is $4.21 and its 200-day simple moving average is $8.53. Indaptus Therapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $47.60.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Wednesday, August 13th. The company reported ($9.09) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($8.73). On average, research analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.